Association between tyrosine-kinase inhibitor induced hypertension and treatment outcomes in metastatic renal cancer.

Gadd, Monique; Pranavan, Ganes; Malik, Laeeq

Gadd, Monique; Pranavan, Ganes; Malik, Laeeq.

Affiliation

Gadd M; Australian National University Medical School, Australian National University, Acton, Australia.
Pranavan G; Australian National University Medical School, Australian National University, Acton, Australia.
Malik L; Department of Medical Oncology, The Canberra Hospital, Garran, Australia.

Cancer Rep (Hoboken) ; 3(5): e1275, 2020 10.

Article in En | MEDLINE | ID: mdl-32767664

Subject(s)

Carcinoma, Renal Cell/therapy; Hypertension/epidemiology; Kidney Neoplasms/therapy; Protein Kinase Inhibitors/adverse effects; Carcinoma, Renal Cell/mortality; Carcinoma, Renal Cell/secondary; Chemotherapy, Adjuvant/adverse effects; Chemotherapy, Adjuvant/methods; Disease Progression; Female; Follow-Up Studies; Humans; Hypertension/chemically induced; Hypertension/diagnosis; Kidney Neoplasms/mortality; Kidney Neoplasms/pathology; Male; Middle Aged; Nephrectomy; Prognosis; Progression-Free Survival; Protective Factors; Retrospective Studies; Survival Rate; Treatment Outcome

Key words

TKI; hypertension; renal cancer

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Renal Cell / Protein Kinase Inhibitors / Hypertension / Kidney Neoplasms Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Cancer Rep (Hoboken) Year: 2020 Type: Article Affiliation country: Australia

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google